Candel Therapeutics Inc Stock News

Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potential commercialization of its cancer immunotherapies. The facility includes four tranches, with $50 million drawn at closing.

NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that it has entered into a five-year, $130 million term loan facility with Trinity Capital Inc. (Nasdaq: TRIN) (“Trinity Capital”).

PHOENIX , Oct. 14, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $130 million in growth capital to Candel Therapeutics, Inc. (Nasdaq: CADL) ("Candel"), a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer. Candel Therapeutics is devel...

NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent glioblastoma, and a pub...

Candel Therapeutics has generated favorable phase 3 data supportive of a BLA submission in prostate cancer, but it won't come until the end of next year. In the meantime, the market appears to be anticipating very little forward momentum in other pipeline candidates. CADL presents a high-risk/high-reward situation at this depressed market cap.

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besad...

Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results from a large late-stage study presented at the annual meeting of the American Society for Radiation Oncology. The therapy, also known as aglatimagene besadenovec, was tested in 745 men with interme...

NEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, presented subgroup analyses focused on the radiation regimen from the Company's positive phase 3 clinical trial of CAN-2409 (aglatimagene besadeno...